Cargando…
Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT)...
Autores principales: | Annalisa, Arcari, Simona, Bassi, Lara, Pochintesta, Elena, Trabacchi, Filippo, Moroni Carlo, Angela, Rossi, Luca, Zanlari, Daniele, Vallisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717301/ https://www.ncbi.nlm.nih.gov/pubmed/29234595 http://dx.doi.org/10.1016/j.lrr.2017.11.001 |
Ejemplares similares
-
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019) -
Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023) -
New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
por: Arcari, Annalisa, et al.
Publicado: (2023) -
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019) -
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)